INCYTE CORPORATION

NASDAQ: INCY (Incyte Corporation)

Kemas kini terakhir: 4 jam lalu

100.46

-1.04 (-1.02%)

Penutupan Terdahulu 101.50
Buka 101.20
Jumlah Dagangan 1,982,410
Purata Dagangan (3B) 2,134,053
Modal Pasaran 19,722,577,920
Harga / Pendapatan (P/E TTM) 17.03
Harga / Pendapatan (P/E Ke hadapan) 13.39
Harga / Jualan (P/S) 4.25
Harga / Buku (P/B) 4.29
Julat 52 Minggu
53.56 (-46%) — 109.28 (8%)
Tarikh Pendapatan 28 Oct 2025
Margin Keuntungan 0.48%
Margin Operasi (TTM) 20.65%
EPS Cair (TTM) 0.200
Pertumbuhan Hasil Suku Tahunan (YOY) 19.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -6.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 1.18%
Nisbah Semasa (MRQ) 2.04
Aliran Tunai Operasi (OCF TTM) 382.59 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 618.05 M
Pulangan Atas Aset (ROA TTM) 2.04%
Pulangan Atas Ekuiti (ROE TTM) 0.47%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Incyte Corporation Menaik Menaik

AISkor Stockmoo

0.0
Konsensus Penganalisis -1.5
Aktiviti Orang Dalam 0.0
Volatiliti Harga -1.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 0.5
Purata 0.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
INCY 20 B - 17.03 4.29
ALNY 62 B - 1,682.64 267.34
ABVX 9 B - - 8.74
ONC 37 B - 649.80 8.85
ROIV 14 B - - 3.32
BMRN 10 B - 20.19 1.77

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Core
% Dimiliki oleh Orang Dalam 2.01%
% Dimiliki oleh Institusi 100.65%

Pemilikan

Nama Tarikh Syer Dipegang
Baker Bros. Advisors Lp 30 Sep 2025 30,743,663
Robeco Institutional Asset Management B.V. 30 Sep 2025 2,319,388
Julat 52 Minggu
53.56 (-46%) — 109.28 (8%)
Julat Harga Sasaran
84.00 (-16%) — 125.00 (24%)
Tinggi 125.00 (Guggenheim, 24.43%) Beli
Median 99.50 (-0.96%)
Rendah 84.00 (RBC Capital, -16.39%) Pegang
Purata 102.50 (2.03%)
Jumlah 5 Beli, 3 Pegang
Harga Purata @ Panggilan 93.84
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 24 Nov 2025 115.00 (14.47%) Beli 106.24
29 Oct 2025 101.00 (0.54%) Beli 90.18
Piper Sandler 04 Nov 2025 102.00 (1.53%) Beli 102.92
Guggenheim 03 Nov 2025 125.00 (24.43%) Beli 101.57
RBC Capital 29 Oct 2025 84.00 (-16.38%) Pegang 90.18
24 Sep 2025 81.00 (-19.37%) Pegang 84.16
Truist Securities 29 Oct 2025 93.00 (-7.43%) Pegang 90.18
Wells Fargo 29 Oct 2025 97.00 (-3.44%) Beli 90.18
JP Morgan 09 Oct 2025 89.00 (-11.41%) Pegang 84.75
Stifel 22 Sep 2025 115.00 (14.47%) Beli 84.73
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
HOFFMAN RICHARD A. 102.04 - 9,466 965,911
MORRISSEY MICHAEL JAMES - 102.04 -326 -33,265
STEIN STEVEN H - 101.84 -39,757 -4,044,741
TRAY THOMAS - 104.15 -769 -80,992
Jumlah Keseluruhan Kuantiti Bersih -31,386
Jumlah Keseluruhan Nilai Bersih ($) -3,193,088
Purata Pembelian Keseluruhan ($) 102.04
Purata Jualan Keseluruhan ($) 102.64
Julat Insider ($)
102.04 (1%) — 106.24 (5%)
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
STEIN STEVEN H Pegawai 02 Dec 2025 Jual (-) 20,105 101.44 2,039,451
HOFFMAN RICHARD A. Pegawai 01 Dec 2025 Diperolehi (+) 9,466 102.04 965,911
MORRISSEY MICHAEL JAMES Pegawai 01 Dec 2025 Dibuang (-) 326 102.04 33,265
STEIN STEVEN H Pegawai 01 Dec 2025 Jual (-) 2,559 102.04 261,120
STEIN STEVEN H Pegawai 01 Dec 2025 Dibuang (-) 17,093 102.04 1,744,170
TRAY THOMAS Pegawai 24 Nov 2025 Jual (-) 600 106.24 63,744
TRAY THOMAS Pegawai 21 Nov 2025 Jual (-) 169 102.06 17,248
Tarikh Jenis Butiran
03 Dec 2025 Pengumuman Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Dec 2025 Pengumuman Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
01 Dec 2025 Pengumuman Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
19 Nov 2025 Pengumuman Incyte to Present at Upcoming Investor Conferences
17 Nov 2025 Pengumuman Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)
06 Nov 2025 Pengumuman Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
04 Nov 2025 Pengumuman Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
03 Nov 2025 Pengumuman Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
30 Oct 2025 Pengumuman Incyte to Present at Upcoming Investor Conferences
28 Oct 2025 Pengumuman Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
27 Oct 2025 Pengumuman Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
25 Oct 2025 Pengumuman Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
24 Oct 2025 Pengumuman Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
19 Oct 2025 Pengumuman Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
12 Oct 2025 Pengumuman Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
08 Oct 2025 Pengumuman Incyte to Report Third Quarter Financial Results
24 Sep 2025 Pengumuman Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 Sep 2025 Pengumuman Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
18 Sep 2025 Pengumuman Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
17 Sep 2025 Pengumuman Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
10 Sep 2025 Pengumuman Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda